The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative Study

Yuzuncu Yil University50 enrolled

Overview

We aimed to evaluate the usability and efficacy of omalizumab in allergic rhinitis and its potential as an alternative treatment option.

The study was conducted to determine the effectiveness of omalizumab on symptoms in patients diagnosed with allergic rhinitis and to compare it with current medical treatment options.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Allergic Rhinitis

Interventions

OmalizumabDRUG

The patients in the study group were started on omalizumab and intranasal fluticasone propionate. Omalizumab was administered subcutaneously to these patients at a dose of 300 mg once a month. . Twenty-five patients in the control group were started on intranasal fluticasone propionate spray and a tablet containing 5 mg desloratadine+10 mg montelukast sodium at the same dose and in the same manner as the patients in the study group. The patients were asked to use 100 mg of suspension equivalent to 50 micrograms of fluticasone propionate as two sprays into each nostril once daily and to use the tablet once daily. Patients in both groups were asked to fill out the visual analog scale and their total Ig E levels were checked. Patients who were called for a check-up after eight to ten weeks were evaluated again with the visual analog scale.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Those who gave informed consent and wanted to participate in the study and did not have any additional systemic or nasal diseases were included. Exclusion Criteria: * under 18 years old, * over 65 years old, * with systemic comorbidities (diabetes mellitus, hypertension, chronic renal failure, hypothyroidism, etc.) * patients with rhinosinusitis, nasal polyps, nasal septal deviation, tumors, smoking and nasal surgery, and non-compliant patients were excluded from this study.

Locations (1)

Yuzuncu Yıl üniversity dursun odabaş medical center

Van, tuşba, Turkey (Türkiye)

Outcomes

Primary Outcomes

omalizumab treatment process

Vas scores including runny nose, nasal congestion, sneezing, tearing and itching in the eyes were compared before and 3 months after omalizumab treatment.

Time frame: Patients were followed up for 3 months after starting treatment.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.